At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 60 enrolled
Drug / intervention
Mirikizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Relative Bioavailability of a Mirikizumab Test Formulation Compared to the Reference Formulation in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Mirikizumab for Healthy. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The purpose of this study is to compare two different formulations of mirikizumab in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will also be collected. Participants will remain in the study for about 12 weeks, after receiving study drug.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartSep 2020
First PostedSep 2020
Primary CompletionJan 2021
TodayJul 2026
First PostedSep 14, 2020
Enrollment StartSep 11, 2020
Primary CompletionJan 11, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.8 years ago
Interventions
Mirikizumabdrug
Reference and test formulations of mirikizumab administered as a SC injection.